The University of Chicago has had a major commitment to both laboratory and clinical cancer research since 1930. As part of the clinical translation of that research, the University of Chicago and its Cancer Research Center joined the Cancer and Leukemia Group B (CALGB) in 1985, and has subsequently strongly supported the CALGB both scientifically and clinically. Numerous protocols, committees, and programs are lead by Chicago faculty. Over the past five years the University of Chicago has increased its accrual from 184 patient points to 294 patient points, and in 1996 27 percent of the main member's patient accrual was African American. These accomplishments occurred by disciplined activity at the main member and also by supporting seven dedicated affiliated institutions in northern Illinois, Michigan and Indiana. Chicago is in the process of adding three new affiliates in the next year and remains very involved with the training and quality control of all its affiliate institutions. The goals of this application are: (1) increase the patient accrual to 300-350 patients/year; (2) to lead and assist CALGB scientific activities in the disease-related committees of respiratory (Drs. Vokes and Olak), prostate (Drs. Vogelzang, Steinberg and Vijaykumar), breast (Dr. Fleming), leukemia (Dr. Larson) and GI (Dr. Mani); (3) to lead and assist and participate in the CALGB committees such as psycho/oncology (Marcy List, Ph.D.), pharmacology and experimental therapeutics (Dr. Ratain), transplantation (Dr. Williams), genetics (Dr. Olopade), AIDS related malignancies (Dr. Liebowitz), surgical oncology (Dr. Michelassi) and pathology (Dr. Vardiman); (4) to encourage Chicago faculty to be protocol chairs for future protocols; and (5) to actively assist and participate in the CALGB committees of audit, minority issues, oncology nursing, cancer control, and radiotherapy. The University of Chicago proposes to accomplish these goals by the following methods: (1) to increase accrual from the main member with the assistance of new energetic physicians in colorectal, breast, surgery, leukemia and prostate cancer and by generating new ideas for phase I, II and III protocols; (2) to maintain the high accrual from the affiliate hospitals and increasing accrual by adding new qualified affiliates; (3) to maintain the strong leadership roles of Drs. Vogelzang, Vokes, Larson, Schilsky, Ratain, Williams, Olopade, List, Vardiman and Michelassi within the CALGB; (4) to recruit new young investigators to CALGB leadership roles (Drs. Manni, Leibowitz and Daugherty); especially those with a specific laboratory expertise which can be correlated with clinical treatment or outcome; and (5) to provide volunteers for numerous CALGB administrative committees. The University of Chicago and its affiliates remain firmly committed to serving all members of their respective communities, especially serving the needs of women and minorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA041287-15
Application #
6172045
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1986-09-30
Project End
2003-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
15
Fiscal Year
2000
Total Cost
$287,592
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050

Showing the most recent 10 out of 224 publications